此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

通过 CD34 选择去除动员外周血干细胞的体外 T 细胞 (EXCESS)

2026年11月11日 更新者:Robert Krance、Baylor College of Medicine

通过 CD34 选择 (EXCESS) 去除动员外周血干细胞的体外 T 细胞

Participants are being asked to take part in this study because treatment of his or her disease requires a stem cell transplant. Stem cells or "mother" cells are the source of normal blood cells and lead to recovery of blood counts after bone marrow transplantation. Unfortunately, there is not a perfectly matched stem cell donor (like a sister or brother) for the participant and his or her disease does not permit enough time to identify another donor (like someone from a registry list that is not his or her relative) or another suitable donor has not been identified. However, a close relative of the patient has been identified whose stem cells are not a perfect match, but can be used.

Alternatively, the patient may have already received a stem cell transplant but have evidence of mixed chimerism, which means some of the patient's own bone marrow cells are present, rather than all of the donor's cells. This may lead to an increased risk of the disease coming back. Or, the patient may have all donor cells but his or her bone marrow is not working very well, which may lead to frequent blood or platelet (cells that help in clotting blood) transfusions or infection.

Regardless of the reason, it may be necessary to isolate stem cells from a haploidentical (half-match) donor in order to provide bone marrow function. Because the stem cells from the donor are only half-matched to the participant, the risk of graft-versus-host disease (GvHD) is very high. GvHD is a complication after transplant caused by donor T cells (graft) that attack the transplant recipient, and this complication can cause death after transplant. Thus, it is important that the donor's blood cells are treated to minimize cells that are most likely to attack the host's tissues. This is done by using a special device to capture the CD34+ stem cells from the donor's stem cell product prior to giving the cells to the host. This method minimizes the donor T cells, which are responsible for causing GvHD.

Purpose: In an effort to lower the occurrences and severity of graft-versus-host disease in patients and to lower the rate of transplant failure, investigators would like to specially treat the donor's blood cells to minimize the cells that are most likely to attack the patient's tissues.

研究概览

详细说明

Participation in this project will last approximately one year with follow-up exams.

Before treatment can begin, stem cells will be collected from the donor (a close relative) that has been selected as the best match for the participant. White blood cells will be collected from the donor. The cells will then be mixed with a special protein, called a CD34 antibody, that binds to the stem cells, which will then be separated out from the white blood cells by a special machine- called a CliniMACS CD34 Reagent System in the laboratory. This is an investigational device that is not approved by the FDA. Although this device is not approved for use in this country, it has been in use for years and is approved in other countries. The stem cells will be collected and given fresh or they can be frozen before they will be given to the participant.

On about days 28, 60, 100, 180 and 365 after the transplant, the participant will have the same tests/evaluations since the time of transplant. For patients who do not develop GvHD, they are not required to have these tests/evaluations.

In addition, for purposes of the study, health-related information will be collected for a year from the time of stem cell infusion. This will be used to determine survival, relapse, infections and GvHD that may occur following transplant.

研究类型

介入性

注册 (估计的)

241

阶段

  • 不适用

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

  • 姓名:Marlen Dinu
  • 电话号码:832-824-4881
  • 邮箱:mxdinu@txch.org

研究联系人备份

学习地点

    • Texas
      • Houston、Texas、美国、77030
        • 招聘中
        • Houston Methodist Hospital
        • 接触:
        • 接触:
      • Houston、Texas、美国、77030
        • 招聘中
        • Texas Children's Hospital
        • 接触:
        • 接触:

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

不超过 70年 (孩子、成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion criteria for Stem Cell Transplant WITH Conditioning (COHORT 1)

  1. Patient requiring allogeneic SCT
  2. Age between birth and 70 years
  3. Patient and/or responsible person able to understand and sign consent

Exclusion criteria for Stem Cell Transplant WITH Conditioning (COHORT 1)

  1. Active, acute GvHD > grade II or extensive, chronic GvHD
  2. Severe life, threatening infection
  3. Pulmonary dysfunction (FEV1, FVC or DLCO 40% of predicted or 3 SD below normal)
  4. Cardiac dysfunction (LVSF less than 25%)
  5. Psychiatric disturbance
  6. Lansky or Karnofsky score < 50%
  7. The presence of severe hepatic disease (direct bilirubin >3x upper limit of normal and AST > 5x upper limit of normal).
  8. Creatinine > 3x normal
  9. Known HIV Positivity
  10. Pregnancy

Inclusion Criteria for CD34+ Topoff WITHOUT conditioning (COHORT 2)

  1. Allogeneic SCT Recipient requiring additional cellular therapy

  2. Age between birth and 70 years

  3. Patient and/or responsible person able to understand and sign consent

  4. At least ONE of the following must be answered YES for a patient to be eligible to receive CD34+ topoff:

    1. Evidence of mixed chimerisms (less than 95% donor cells)
    2. Evidence of poor bone marrow function (bone marrow cellularity less than 50% with at least one cytopenia)
    3. Relapsed or persistent disease

Exclusion criteria for CD34+ Topoff WITHOUT conditioning (COHORT 2)

  1. Active, acute GvHD > grade II or extensive, chronic GvHD
  2. Severe life, threatening infection
  3. Known HIV positivity
  4. Pregnancy

Inclusion Criteria for CD34+ Topoff WITH conditioning (COHORT 3)

  1. Allogeneic SCT Recipient requiring additional cellular therapy

  2. Age between birth and 70 years

  3. Patient and/or responsible person able to understand and sign consent

  4. At least ONE of the following must be answered YES for a patient to be eligible to receive CD34+ topoff:

    1. Evidence of mixed chimerisms (less than 95% donor cells)
    2. Evidence of poor bone marrow function (bone marrow cellularity less than 50% with at least one cytopenia)
    3. Relapsed or persistent disease

Exclusion criteria for CD34+ Topoff WITH Conditioning (COHORT 3)

  1. Active, acute GVHD > grade II or extensive, chronic GvHD
  2. Severe life, threatening infection
  3. Pulmonary disfunction (FEV1, FVC or DLCO 40% of predicted or 3 SD below normal)
  4. Cardiac dysfunction (LVSF less than 25%)
  5. Psychiatric disturbance
  6. Lansky or Karnofsky score < 50%
  7. The presence of severe hepatic disease (direct bilirubin > 3x upper limit of normal and AST > 5x upper limit of normal)
  8. Creatinine > 3x normal
  9. Known HIV positivity
  10. Pregnancy

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:非随机化
  • 介入模型:并行分配
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
实验性的:Cohort 2: CD34+ cells as a top off Without Conditioning

Cohort 2 consists of patients needing additional CD34+ stem cells collected by 'CliniMACS CD34 Reagent system' as a "topoff" without the need for additional conditioning prior to the infusion. These patients who have already received SCT and are receiving CD34+ cells from their original donor for poor graft function, declining chimerism or disease relapse.

A special machine that separates out the donor cells that have been mixed with a special protein, CD34 antibody, that binds to the stem cells from the white blood cells.

实验性的:Cohort 1: CD34+ Cells for transplant

Cohort 1 consists of patients receiving CD34+ selected peripheral blood stem cell transplant with a preceding conditioning regimen (chemotherapy with, or without, radiation). The stem cells will then be separated out from the white blood cells by a special machine- called a CliniMACS CD34 Reagent System in the laboratory.

A special machine that separates out the donor cells that have been mixed with a special protein, CD34 antibody, that binds to the stem cells from the white blood cells.

实验性的:Cohort 3: CD34+ cells as a top off With Conditioning

Cohort 3 consists of patients needing additional CD34+ stem cells collected by 'CliniMACS CD 34+ Reagent System' as a "topoff" with the need for additional conditioning prior to the infusion. These patients who have already received SCT with conditioning and are receiving CD34+ cells from their original donor for poor graft function, declining chimerism or disease relapse.

A special machine that separates out the donor cells that have been mixed with a special protein, CD34 antibody, that binds to the stem cells from the white blood cells.

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
For Cohort 1: the rate of primary engraftment 50 days post SCT
大体时间:50 days

Primary engraftment is defined as achievement of absolute neutrophil count (ANC) is greater than or equal to 500/ul for three consecutive days by day 50 post transplant. The treatment regimen will be considered clinically useful if the primary engraftment rate is at least 85%.

50 days
For Cohort 2 (Without Conditioning) and Cohort 3 (With Conditioning): The total incidence of overall acute GvHD (greater than or equal to grade 3)
大体时间:100 days

The overall incidence of acute GvHD will be measured 100 days post stem cell transplant. The regimen will be considered acceptable if aGvHD greater than or equal to grade 3 rate is at least 10% or lower.

100 days

次要结果测量

结果测量
措施说明
大体时间
Assessment of Long Term Survival
大体时间:1 year

Long term survival of recipients of G-CSF mobilized peripheral blood stem cells depleted of T cells by positive selection for the CD34+ antigen

1 year

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 首席研究员:Robert Krance, MD、Baylor College of Medicine

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2010年10月1日

初级完成 (估计的)

2027年10月1日

研究完成 (估计的)

2027年11月1日

研究注册日期

首次提交

2010年8月25日

首先提交符合 QC 标准的

2010年8月25日

首次发布 (估计的)

2010年8月27日

研究记录更新

最后更新发布 (实际的)

2026年11月16日

上次提交的符合 QC 标准的更新

2026年11月11日

最后验证

2026年11月1日

更多信息

与本研究相关的术语

其他研究编号

  • H-27251 EXCESS
  • EXCESS (其他标识符:Baylor College of Medicine)

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

是的

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅